Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Roots of Related Genetic Diseases Found in Cell Powerhouses

By New York University School of Medicine | January 20, 2017

Scientists at NYU Langone Medical Center have discovered the mechanisms behind a genetic change known to cause a set of related diseases.

A new study, published in the journal Molecular Cell online Jan. 19, shows how errors in the genetic code—introduced as it is copied and passed along to the next generation of cells—frequently result in damage and mismanaged repair attempts that end with the deletion of a stretch of 4,977 base pairs, the molecular letters that make up DNA.

Researchers say this large loss of genetic material is very widespread and why it is known as “the common deletion.” Among the diseases linked to the common deletion are Pearson’s syndrome, which can result in blood cell shortages; Kearns-Sayre syndrome, which can lead to deafness; and chronic progressive external ophthalmoplegia, which is known to cause eye muscle weakness. It has also been linked to several cancers, and occurs with greater frequency in cells as people age.

Interestingly, the researchers point out, the common deletion does not occur in the 30,000 genes in the cell’s nucleus that encode the blueprint for the human body. Instead, the common deletion, and the focus of their latest study, revolves around a second set of DNA that lies outside the nucleus, and is composed of 37 genes in each mitochondrion, the “powerhouse” compartment that turns sugar into cellular energy.

Fewer in number and energy focused, mitochondrial genes have traditionally received relatively scant attention from researchers seeking to understand disease risk, the scientists say. Since the common deletion was first identified in the 1980s, some 200 deletions in mitochondrial DNA have been linked to disease, although no estimates yet exist as to how many people are affected by it or how frequently such deletions impair health.

“Our study suggests that we have not only found the mechanism behind the common deletion in mitochondria and precisely how this type of DNA is copied, but perhaps a mechanism behind many disease-related deletions,” says senior study investigator Agnel Sfeir, Ph.D.

“Although we are a long way from testing potential treatments, our short-term goal is to identify biological pathways that could become the targets of future drugs that stop, reverse, or prevent mitochondrial diseases,” says Sfeir, an assistant professor at NYU Langone and its Skirball Institute for Biomolecular Medicine.

According to researchers, better-known nuclear DNA is organized differently than mitochondrial DNA (mtDNA). Both are double-stranded, connected chains of DNA. But unlike nuclear DNA, which is linear in shape, mtDNA is circular.

In laboratory experiments, some in human cells and others in mouse cells, researchers found that the process for copying mtDNA (or replication), an essential aspect to energy production, is prone to stalling. This stalling, researchers say, makes the DNA more susceptible to breakages. Attempts to repair the break will result in the common deletion.

Another key study finding resolved a long-standing question in basic biology about how mtDNA copies itself. Using a chemical-labeling technique developed at NYU Langone that allowed researchers to analyze individual molecules of mtDNA, they found that the replication process was not uniform. Each circular strand of mtDNA is copied from a different starting point, a theory of strand displacement that had initially been proposed in the 1970s.

 


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE